计划生育市场报告 2022.12

ReproductiveHealthSUPPLIESCOALITION4GLOBALMARKETSVISIBILITYPROJECTACKNOWL前十国家其他中低收入国家!!相较于2020年有收缩，但从2017年至2021年市场总值有相较于2020年有收缩，但从2017年至2021年市场总值有*本图中前十的国家以2021年的数据为依据，按字母顺序排列为：孟加拉、布基纳法索、刚果民主共和国、埃塞俄比亚、马拉维、莫桑比基于2021年CYP出货量的各种避孕方法市场份额对各种方法进行分析就2020-2021的CYP出货量而言增长最大对各种方法进行分析就2020-2021的CYP出货量而言增长最大铜制IUDs铜制IUDs注射避孕药物男用避孕套含激素IUDs女用避孕套0.6%第一次在报告中增加本方法33UNFPA在2021财年的避孕药具采购总主要原因是受新冠疫情影响，2021UNFPA在2021财年的避孕药具采购总主要原因是受新冠疫情影响，2021年英国外交、联邦和发展事务部(USAID在2021财年的避孕药具采购总在2017财年至2021财年的典型波动2022年《计划生育市场报告》（FamilyPlanningMarketReport）介绍2021年83个中低收入国家（LowerMiddleIn场概况。此前的市场报告侧重于69个FP2020重点国家，而今年出了更新，涵盖了83个中低收入国家，地理范围进一步扩大，这些国家现于2021年宣布的性与生殖健康（SexualAndReproductiveHealth购的数量，如美国国际开发署（UnitedStatesforInternationalDevelopment，U基金（UnitedNationsPopulationFund，U83个中低收入国家的卫生部、政府关联销组织（SocialMarketingOrganization，采集自17家供应商，避孕方法涵盖女用康用品可视化系统（ReproductiveHealthSVisualizer，RHViz）中的发货数2021年，公共部门市场价值相对于年，2021年的市场容量也下降了15门市场的避孕产品的夫妻避孕年（CoupleYe激素口服避孕药的数量减少所导致的。与2017-2020年期间一样，长效可逆避孕方法（Long-ActingMethodsofContraception-LARC），包括皮埋、铜制和激素型IUD）仍然是2021年公共部门市场已出货类别的数据却有所变化：从2020年至201这83个中低收入国家按照截至2020年的世界银行收入分类进行定义。有关FP2030将报告数据的中低收入国家的更多信息，请参见：/sites/default/files/Data-Hub/FP2030_DataReport_v5.pdf。请注意，FP2030报告涵盖82个中等收入国家，比《计划生育市场报告》涵盖的83个国家少一个。在一定程度数据，FP2030目前未报告西撒哈拉（之前是69个FP2020重点国家之一）的相关数据。然而，在与FP2030范围内，因此共涵盖83个中低收入国家。为确保国家范围在报告所涵盖的所有年份中保持一致，从供应商处收集了2017-22IUD是宫内节育器的缩写。由于公开的激素型IUD价格于2021年首次纳入U3此报告长期以来使用生殖健康交流中心（ReproductiveHealthInterchange，RHI）的数据来估计男用避孕套市场的规模。由于男用避孕套市场相当分散，RHI长期以来针对该避孕方法提供了较高的可见性。此外，RHI数据也一直用于评估《计划生育市场报告》所涵盖的所有避孕方法的相对可见性。然而，2020年9月，SRH社区从RHI生殖健康用品可视化系统(RHViz)。因此，2022年《计划生育市场报告》现采用RHViz44夫妻避孕年(CYP)是指避孕方法在一年内提供的估计避孕效果（例如，120只避孕套可为一对夫妻提供一年的避孕效果）。对于所有CYP计4本节分析了2017年至2021年公共部门市场的竺竺元收缩至2021年的2.63亿美元，但仍高于83个中低收入国家的公共部门避孕市场总长，但在2020年达到峰值后，市值从少，这种产品成本相对较低，但CYP降600万）以及复方和纯孕激素口服避孕），CYP始终保持上升趋势。但男用避孕套（增加200万）就2017年至2021年间的地区至2021年，亚太地区的市场份额增加了达到28%，但在2017-2021年期间，位（附件7）。在本报告所涉及的公共部门市年的1.59亿美元（附件9）。虽然逐年变化，但从2017年至2021年幽幽从2020年到2021年，市值量从2020年的600万件下降至2021年的400万件(从2020年至2021年，尼日6私营部门避孕用品的使用并未计入这些市场份额数据。此外，一些从孟加拉国和印度等市场的国内供应商处采购的产品可能未包含在参与供应商的发货数据中。因此，还应注意的是，市场份额估计值仅基于参与供应商的可用发货数据。有关孟加拉国和印度市场的更多详57如前所述，《计划生育市场报告》基于参与供应商的数据，介绍了孟加拉国的避孕用品采购趋势概况。但是，除《计划生育市场报告》中记录的参与供应商外，孟58由于铜制IUD的保质期较长（约3-7年）且避孕周期也较长（放置后最长可达12年其采购周期在2020年达到6800万美元的高位后年至2021年的避孕注射剂总体下降量降量约占40%。孟加拉国在2020年采孕注射剂，因此2021年孟加拉国避孕1）。口服避孕药的发货量也从2020年的2.2021年的2.57亿（附件2）。多个国家注：虽然采购周期波动和上述其他因素促成了2020年69激素型IUD引进工作得到了激素型IUD获取小组的支持，该小组是一个由政府、出资方、制造商、采购机构（UNFPA和USAID/GHSC-PSM）、研究人员和服务提供伙球合作联盟，旨在通过确保提供价格合理、质量有保证的产品来促进市场可持续发展，同时为准备引进该方法及扩大其使用规模的国家（例如，政府对该方法表现出定引进计划等）提供支持，从而扩大中低收入国家获得激素型IUD的机会。6Exhibit1:Valueofthepublic-sectormarket(USD)TotalMarketSize(MillionsUSD) .●Condoms-Male●Condoms-FemaleInjectablesOrals-Emergency●Orals-CombinedandProgestinOnly.HormonalIUDs●ImplantsInjectablesImplants-8%**CompoundAnnualGrowthRate(CAGR):[(finalvalue/beginniNote:Thesumofindividualstackedbarsforallexhibitsmaydifferslightlyfromtotalsduetorounding.Additionally,yearoveryearandcompoundannualgrowthratenumbersarecalculatedthroughoutthereportusingactualvalues,nottheroundedvaluesinthechart.Somedifferencesexistinthehistoricaldatafor2017-2020inthisversionofthesomesupplierorRHVizrevisionstohistoricaldata,basedonupdat8Exhibit2:Totalpublic-sectormarketvolumes(malecondomsexcluded*)ShipmentVolumes(Millions)●Condoms-Female●InjectablesOrals-Emergency●Orals-CombinedandProgestinOnly.HormonalIUDs●ImplantsInjectablesImplants*MalecondomsareshownseparatelybecausethesourceoftheshipmentdataisRHViz,whereasallothermethodNote:Thesumofindividualstackedbarsforallexhibitsmaydifferslightlyfromtotalsduetorounding.Additionally,yearoveryearandcompoundannualgrowthratenumbersarecalculatedthroughoutthereportusingactualvalues,nottheroundedvaluesinthechart.Somedifferencesexistinthehistoricaldatafor2017-2020inthisversionofthereportversuspreviousverwellassomesupplierorRHVizrevisionstohistoricaldata,basedonu9ExhibitExhibit3:CYPsshippedtothepublic-sectormarket(Millions)00 57M●Condoms-Male●Condoms-FemaleInjectables●Orals-CombinedandProgestinOnly.HormonalIUDs●ImplantsInjectablesImplantsNote:Thesumofindividualstackedbarsforallexhibitsmaydifferslightlyfromtotalsduetorounding.Additionally,yearoveryearandcompoundannualgrowthratenumberswerecalculatedthroughoutthereportusingactualvalues,nottheroundedvaluesinthechart.Somedifferencesexistinthehistoricaldatafor2017-2020inthisversionofthereportversuspreviousverswellassomesupplierorRHVizrevisionstohistoricaldata,basedonupInjectables-2monthInjectables-3monthN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AImplants-5YearIUDs(hormonal)Condoms-Male Injectables-3month Orals-CombinedOrals-ProgestinOnly Implants-3Year Injectables-2monthContraceptivePriceIndicatorhaslistedseparatepricesforthe3-yearand5-yeapriceforthisillustrativecostperCYPcalculation.ExhibitExhibit5:CYPmix(intermsofCYPsshipped)inthepublic-sectormarketshipped●Condoms-Male●Injectables●Orals-CombinedandProgestinOnly●Implants39%Note:Somedifferencesexistinthehistoricaldatafor2017-2020inthisversionofthereportversuspreviousversionsduetothedifferentgeographicscopeofExhibit6:Marketsharepermethodinthepublic-sectormarket(USD)MarketValue●Condoms-Male●Condoms-FemaleInjectablesOrals-Emergency●Orals-CombinedandProgestinOnly.HormonalIUDs●Implants38%Note:Somedifferencesexistinthehistoricaldatafor2017-2020inthisversionofthereportversuspreviousversionsduetothedifferentgeographicscopeofExhibit7:Marketshareofpublicsectorbyregion(USD)Market●FinalDestinationCountryNotSpecified.Sub-SaharanAfrica●MiddleEast&NorthAfrica●Asia&Pacific●LatinAmerica&CaribbeanNote:Public-sector,regionalmarketshareshowninthegraphabasmallnumberofcountriesfromboththeLatinAmerica&theseregionsarenot“Destinationcountrynotspecified”indicatesthatshipmentswerereceivedinwarehousesforlaterdistributiontoLMICs.Somedifferencesexistinthehistoricaldatafor2inthisversionofthereportversuspreviousversionsduetothedifferentsupplierscope,aswellassomesupplierorRHVizrevisionstohistoExhibit8:Toptencountriesintermsofvalue,2021Bangladesh Nigeria EthiopiaMozambiqueZambiaDemocraticRepublicofCongo Malawi Exhibit9:Valueof10largestpublic-sectorcountriescomparedtovalueofallothercountriescombined Note:Somedifferencesexistinthehistoricaldatafor2017-2020inthisversionofthereportversuspreviousversionsduetothedifferentgeographicscopeofbasedonupdatedinformation.本节重点介绍来自UNFPA采购事务处及USAID“避孕用品与避孕套发货概述”ContraceptiveandCondomShipments)报告中的数据10，以便了解在2017-2021期间，UNFPA在避有所下降，但仍保持在从2017-20UNFPA在避孕用品采购方面的支出总额（包括UNF的支出仍高于2017年9700万美元的五年周期低位(所以有所下降，是因为UNFPA当年（OfficialDevelopmentActivities-O其中包括将其对UNFPA物资供应项目的2021年的资金缺口。14方面在整体支出大幅下降，但第三方采购占UNF20%。具体而言，从2020财年至2021增加了约700万美元（增长50%而间，第三方采购占UNFPA年度中低收对于USAID，2021财年（不包括男用和女用避孕套）15年USAID《避孕用品与避孕套发货概内筹资）、采购周期引起的波动以及新冠疫情。决定。正如USAID报告中所提到的，随着US施其“自力更生之旅”(JourneytoSelf-Reli略，USAID在某些国家的驻外使团可能10在2018年《计划生育市场报告》发表之前，CHAI和RHSC采用RHI的数据进行全球采购方支出分析。此后，《计划生育市场报告》采用了来自UNF11从2020年至2021年，全球采购方支出的下降幅度大于根据供应商发货数据得出的83个中低收入国家公共部门市值的下降幅度，部分原因在于供应商发货数据包括孟加拉国和印度等国家的采购数据，这些国家利用部分国内资金来采购避孕用品，而全球采购方支出数据中并未包含这类国内资金。此外，供应商发货分析采用UNFPA避孕价计算总市值，因为这是定期更新的公开数据来源，但实际定价12/press/statement-uk-government-funding-cuts13/press/support-france-safeguard-health-and-lives-millions-women-and-girls?page=27,/u-s-engagement-with-the-un-14/unfpa-supplies-annual-report-202115USAID关于避孕用品发货的数据取自“2021财年避孕用品与避孕套发货概述报告”。2021财年的报告反映了计划生育供资情况，但不包括H我们排除了2017财年至2021财年的女用和男用避孕套的市值，以比较不同年份的同一数据集。USAID报告可在此获得：/sites/default17USAID的“自力更生之旅”战略旨在促进与东道国政府的合作，以加强地方能力、调动公共和私营部门收入并加速以企业为驱动的发展/documents/1870/journey-self-reliance-fact-sheShipmentValuestoFP2020$200M$0MExhibit11:USAIDprocurementvalue(excludingmaleandfemalecondoms)–ShipmentValuestoFP2020$40M$0M支出有所下降（这主要是由2021年），CommonwealthandDevelopmentOffice，FC造成的）。经过不断努力，UNFPA的预回弹，达到与2021年之前相当的水平瞻性综合预算的一部分，UNFPA表示，UNFPA2025财年的整体收入预测预计将与201年的平均避孕用品采购支出约为每年1.预测，这意味着UNFPA在未来几年宣布削减20.5亿美元的援助预算，但据了解，国际发展国务大臣AndrewMitche保障人道主义援助支出和妇女及女童方面的援助支2017-2021财年，USAID在避孕孕用品采购支出水平，USAID也将继续品采购的资金需求很可能会继续增长。据18/press/statement-executive-director-unfpa-integrated-budget-2022-2025-second-regular-session19/news/uk-aid-faces-third-major-cut-in-3-years-with-1-7b-to-be-cut-104513212022年3月28日，美国总统拜登向美国国会公布高了9%。拟向UNFPA提供的资金从2022相关项目”（State,ForeignOperations,andRelatedProgram，SFOP）拨款法案报告，其中提出了超出政府预算要求的资金。该法案中包括的双边FP/RH资金总额为8美元，为UNFPA总计拨款7000万美元。20资金并为UNFPA提供6000万美元的资金。在本文撰写之时，预算对话尚在进行中。有关信息，请访问：/news-summary/white-house-releases-fy-2budget-request/;/news-summary/house-appropriations-committee-releases-the-fy23-state-and-foreign-operations-sfops-appropriations-bil/news-summary/senate-appropriations-committee-releases-fy23-state-and-foreign-operations-sfops-and-labor-health-and-human-services-lahhs-appropriations-bi23WeinbergerM、EvaG、GoldJ、BellowsN、ReidyM、SandersR和SkibiakJ。LEAP：生殖健康供应需求的前景与预测。生殖健康用品联盟，2021。报告可参见https:///#/在讨论2017-2021年的市场趋势感到惊讶，因为FCDO在2021年宣的努力表示赞赏。SRH社区在以下方面作出了积极包括：在全球计生市场可视化与分析网络（VisibilitAnalyticsNetwork，VAN）的帮助下，24确定应缺口；UNFPASupplies在这一年为了减轻FCDO提供给UNFPA的资金水平迈进。利益相关者还建议UNFPA汲和交付周期延长一直持续到了2021输成本相对较高。例如，据USAID报间的长期相互影响。例如，一些国家在引入激提供针对各国避孕用品分配或消费的看法。年到2021年，避孕用品采购市值有所下货数据并不能用于推断2020年至2021过去几年来，全球新冠疫情和严峻的经济形24https://www.rhsupplies.or25/its-about-supplies/how-greater-data-visibility-helped-the-reproductive-health-community-confront-the-challenges-of-f02bdb9324ba26/press/support-france-safeguard-health-and-lives-millions-women-and-girls?page=27,/u-s-engagement-with-the-un-27/updates/international-freight-alert282021年8月，USAID对USAID监察长办公室的信息请求作出的回应。网址：/sites/default/files/2021-11/COVID-19%20Information%2029如2016年RHSC“商品差距分析”（CommodityGapAnalysis）中所述，一般采购趋势“也可能反映了除用户消费之外的一些因素，例如填充从中央仓库到各个服务交付点的供应管道及维持充足库存水平所需的数量。采购数量可能会考虑已经存在或订购的供应量、供应链上的库存持有政策以及各级供应品的浪费或“泄漏”。资金限制、施、未来推广项目计划以及出资方或政府本身对特定方法或产品的偏好也可能会影响要采购的供应品类型和数量。”链接见（下页）：/uptx_rhscpublications/Global_Contraceptive_Commodity_Gap_Analysis_20initiativethathasprovidedthereproductivehealthcommunitywithdetailedassessmentsofthepublic-Theinitiativeprovidesinsightfulandstrategicoutputssupplierstodevelopandimplementmoreeffectiveplanningproductsandservices.MOUwithCHAIorprovidedtheirinformationthroughcollaborationswiththethenGenericManufacturers17suppliersparticipatingintheproject.Thetotalpublic-sectormarketreferencedinthisreportonlyincludesdataforthepublicsector,whichisdefinedtheUnitedStatesAgencyforIntministriesofhealth,governmentaffiliatedprocurersasAlthoughsignificanteffortshavebeenmadetocollectasmuchdataaspossible,itdatainthisreportmaynotrepresenttheentiretyofcontraceptiveprocurementforthepublicsector.Thisreportincludesdatafrommost,butnotall,suppliersassociatedwiththesemark(inalphabeticalorder)corecompetenciesinhealthcareandacontraceptiveproductportfolioincludescontraceptiveinjectables.CiplaLimitedisanIndia-bahealth.Itscontraceptiveproductportfolioincludesemergencycontraceptivesandcombinedoralcontraceptives.ItalsomanufacturesmisoprostCorporateChannelsmanufactureroffemalecontraceptivedevicesbasedinprovidepermanentcontraceptionforwomen.isamanufacturerofreproductivehealthproductsbasedinChina.ItscontraceptiveproductportfolioincludesemergencyoralcontraceptivesandcombinedoralCupidLimitedisamanufacturerofbothmaleandfemaleandresearchanddevelopmandmanufacturingofitsownbrandedproducts.30TheprocurementofproductsusedforsterilizationsuchastubalringsarenotcoveredinthisdivisionofVeruHealthcarefocusingonurologyandprotectionagainstsexuallytransmittedinfectionsandInceptaandmarketsgenericdrugacrossvarioustherapeuticareas.Inceptacurrentlyexportsitsproductsto83countriesaroundtheworld.Itscontraceptiveproductportfolioincludesoral(combinedandprogestinonly)andinjectablecontraceptives.Medicines360healthpharmaceuticalcompanythatseekstocatalyzeequitableaccesstomedicinesanddevicesthproductdevelopment,policyadvocacy,andcollaborationcontraceptiveproductportfolioincludescontraceptivesterileapplicator),oralcontraceptives(Exlutonandcontraceptiveproductportfolioincludes3-monthPregnaisamanufacturerofbasedinIndia.Itscontraceptiveproductportfolioringsusedforfemalesterilization.reproductivehealthcare.Itscontraceptiveproductportfolioincludesamonthlyinjectable,athreemonthlyinjectable,acombinedoralcontraceptive,andprequalifiedstatus.Bangladesh.Itscontraceptiveproductportfolioincludescombinedoralcontraceptives,progestin-onlyoralcontraceptives,andemergencyoralcontraceptivepills.manufacturerofcontraceptiveimplantsbasedinChina.pre-qualifiedDahua’sLevoplant(foImplantII)forthreeyearsofuse.contraceptiveproductportfolioincludescombinedoralViatris(Mylan)portfolioincludesoralsolids,injectables,anddevices.BurundiDjiboutiKiribati––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––Mauritania–––––––––Philippines–––––––––––––––––––––––––––Timor-Leste––––––––––––––––––––––––––––––––––––––––––––––––––––––ExhibitA.2:83LMICs-ContraceptivemarketvolumesBurundiDjiboutiKiribati–––––––––––––––––––––––––––––––––––––––––––––––––––––ExhibitA.2:83LMICs-ContraceptivemarketvolumesMauritaniaPhilippinesTimor-Leste–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––ExhibitA.2:83LMICs-ContraceptivemarketvolumesExhibitA.2:83LMICs-Contraceptivemarketvolumes–––––––––––––––––––––––––ExhibitA.3:83LMICs-ContraceptivemarketvolumBurundiDjiboutiKiribati––––––––––––––––––––––––––––––––––––––––––––––––––––––––ExhibitA.3:83LMICs-ContraceptivemarketvolumMauritaniaPhilippinesTimor-Leste––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––ExhibitA.3:83LMICs-ContraceptivemarketvolumExhibitA.3:83LMICs-Contraceptivemarketvolum––––––––––––––––––––––ExhibitA.4:83LMICs-Contraceptivemarketvolumesbymethod,2020BurundiDjiboutiKiribati–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––ExhibitA.4:83LMICs-Contraceptivemarketvolumesbymethod,2020MauritaniaPhilippinesTimor-Leste––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––ExhibitA.4:83LMICs-Contraceptivemarketvolumesbymethod,2020ExhibitA.4:83LMICs-Contraceptivemarketvolumesbymethod,2020–––––––––––––––––––––––ExhibitA.5:83LMICs-ContraceptivemarkeBurundiDjiboutiKiribati––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––ExhibitA.5:83LMICs-ContraceptivemarkeMauritaniaPhilippinesTimor-Leste––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––ExhibitA.5:83LMICs-ContraceptivemarkeExhibitA.5:83LMICs-Contraceptivemarke–––––––––––––––––––––––––Indevelopingthisreport’smarketanalyses,adatasourcesfrompartnerorganizationsthatprovidefamilyplanningmarketdataatthegloballevelwereavailablemetrics,coverageofcofupdates,andeaseofaccessappropriatesourcesforsustainableanalyses,thatwillbeprovidesanoverviewofthedatasourcesthisreportFP2020GlobalMarketsVisibilityProjectGlobalMarketsVisibilityProjecsuppliers,andpartnersimprovetheirunderstandingofthecurrentmarketsizeandtrendsforkeycontraceptivedatabyproductandcountryfromsuppliersforeachofthemarketreport’sgeographicscopetoincludethecollectandaggregateshipmentdatafromparticipatingreports,CHAIhascollectedshipmentdatadirectlyfromVisibilityProjecthascollectedhistoricalshipmentdatamanufacturersacrossfivefamilyplanningproductreportintheSupplierShipmentAnalysisandassociatedAppendicesarebasedonthesuppliershipmentdatacollectedthroughthisproject.U.S.AgencyforInternationalreproductivehealthactivitiessiisanannualpublicationthatsummarizescontraceptiveexcludingmaleandfemaleValuesareinclusiveofcommodityandfreightcostsandTheUnitedNationsPopulationFundsystemfortheprocurementofreproductivehealthcommoditiesandhasbeenprocuringreproductiveandtestingandarereportedbasedonReproductiveHealthSuppliescontraceptiveshipmentsvolumesviaaseriesofpublic-procurementshipmentdata(fcomparisonpointforthesupplierdatasetforahigh-levelunderstandingofsuppliershipmentdatacoverage,accordingly,thisreporthasThevalueofthepublic-sectormarketwascalculatedusingthemostcomprehensivehistoricalsupplier-reportedshipmentdataandRHVizshipmentdata.Shipmentdataisrecofollowingunits:ImplantsInjectablesThisyear’smarketreportincludeshistoricalsupplier-planningproductcateItisimportanttonotethattherewereseveralshipmentsthesevolumeswereinitiallyshippedtonon-LMICs,totalshipmentstothe83LMICsafteritwasconwithsuppliersthatthespecificnon-LMICvolumeswereassociatedwithglobalprocurerpurchases.CHAIanalyzedtheaggrreportedshipmentdatatoconfirmthatcoverageacrossthepublic-sectorproductmarketswasgreaterrelativecollectinghistoricalvolumesofallglobalprocurerfromsupplierswastoaddressdatagapsobservedinpubliclyavailableshipmentdatawhichonlycaptureasubsetofprocurerswhochosetosubmithistoricalprocurementdata.Furthermore,althoughsomecountriesreportnationalprocurements,manynationalprocurementsarenotreportedinpubliclyavailablehistoricalsupplier-reportedshipmentvolumestothe83ExhibitC.2:GlobalMarketsVisibilityProjectparticipantsandproducts33Totalshipmentoforalcontraceptivesincludescombined,progestin-only,andemergencyoralcontraceptExhibitExhibitC.3:Supplier-reportedshipmentvolumesto83LMICsbymethod,2017-2021ImplantsExhibitC.4:Supplier-reportedshipmentvolumesasapercentageofRHViz-reportedvolumesImplantsNote:Cumulativetotalscalculatedusingactual,ratherthanroundednumbers.MaleCondomMarketRHVizshipmentdataformalecondomswasusedtocaptureamorecompThesupplier-reportedvolumesforfemalecondoms,implants,injectables,IUDs,andorvolumesformalecondoms,repr34TotalyearlyvolumesarebasedontheyearthattheproductwassTotalPublic-SectorMarketinAllshipmentvolumesweredividedbythecorrespondingtheestimatedprotectionprovidedbydifferentdifferentCYPsassociatedwithseveraldiffeforthree-andfive-yearimplants)thecorrespondingexhibitshowstheconversionfactorsusedtotranslateInjectables-3month64availableat/global-health/health-areas/family-planning/couple-years-protection-cyp.ImplantsInjectablesValueoftheTotalPublic-SectorMarketThetotalvalueofcontraceptiveswascalculatedbyapplyingaverageunitpricestototalshipmentvolumes.AlthoughPriceIndicator,giventheContraceptivePrinotaccountforadditionalcostsassociatedwithprocurementsuchastesting,insurance,andshippingcosts.36UNFPA,“UNFPAContraceptivePriceIndicator—Year2021”,availableat/sites/default/files/resource-pdf/Contraceptive%20Price%20Indicator%202021.pdf,UNFPA,“UNFPAContraceptivePriceIndicator—Year2020”,availableat/sites/default/files/resource-pdf/UNFPA_Contraceptives_Price_Indicator_2020.pdf,UNFPA,“UNFPAContraceptivePriceIndicator—Year2019”,availableat/sites/default/files/resource-pdf/UNFPA_Contraceptive_Price_Indicators_2019_V2_-_EXTERNAL.pdf,UNFPA,“UNFPAContraceptivePriceIndicator–Year2018”,availableat/sites/default/fUNFPA_Contraceptive_Price_Indicators_2018_.pdf,UNFPA,“UNFPAContraceptivePriceIprice-indicator-year-2017.Toprotectcustomerconfidentiality,supplierswerenotaskedtodisclosecustomerinformationassociatedwithshipmenttwomajorglobalprocurersoffamilyplanningcommodities.Formoreinformationoneachofthesedatasources,referGoingforward,CHAIandRHSCcommoditiestoensurethedataprovidedisthemostaccurateandaccessibleforthepurposesofthisreport.ThisreporthashistoricallyincludedsupplementaryresearchandanalysisusingpubliclyavailabledatasourcesinforBangladeshandIndia.Publiclyavailabledataongovernmentpryears,soIndonesiahasbeenremovedfornowGiventhelimitationsofpubliclyavailabledatasources,thisreportcannotconfirmthatthesemarketvisibilityanalysestobeusedasinitialviewintodomesticprocurementinthesemarkets,thatmaynotbefullycoveredbythesuppliersparticipatinginthisreport.Drugs.Althoughdatafromonlyasubsetofthesemanufacturersisincludedinthesuppliershipmentdata,suppliersrepresentedintheFamilyPlanningMarketReportcomprisedalargershipmentanalysestothevolumesfromtheBangladeshMOHFWprocurementdsuppliershipmentdata.AlthoughcontraceptiveprocurementhasfluctuatedinBangladesh,consumptionhasBangladesh’ssupplychainreports42revealedthatconsumptionofcontraceptivecommoditieshasbeenfairlyconsistent4437BangladeshandIndiaaccountedforalargeproportionofthegapbetweenFP2030oncountry-specificcomparisons(per2016analysis,whnotableproportionofthegapbetweenFP2030-reportedusersofproduct-basedmethodsandusersimpliedbytheshipmentdatabutiscurrentlyexcludedfromthemarketvisibilityanalysisgivenlimitedpubliclyavailabledataonprocurementinrecentyears.38NotetheBangladeshMOHFWrecordsprocuremen41ToestimatethemarketvalueinBangladeshanPriceIndicator)throughoutthemarketvisibilityappendix.Actualpricingmaydifferinthesemarketsgiventhedifferentsuppliersandpricingparametersatplay.However,UNFPApriceshavebe